Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

which the regulator has under priority review in bladder cancer. German Merck and Pfizer are now following in the footsteps of Bristol-Myers Squibb (BMS), Merck & Co, and Roche with their ...

A phase 3 trial found that a combination of a Pfizer and Astellas drug ... improved survival rates for patients with advanced bladder cancer. The latest results from the trial, which focused ...

Pfizer also has high hopes for PD-1/PD-L1 inhibitor sasanlimab for non-muscle invasive bladder cancer in the CREST study, and CD3xBCMA bispecific Elrexfio (elranatamab) in MagnetisMM-5 as a ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

is the No. 1 prescribed first-line treatment in the U.S. for locally advanced/metastatic bladder cancer. Late-stage studies could lead to an additional approval that would almost triple the potential ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...

Pfizer and Astellas Pharma have shared positive results from a late-stage study of their antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) in bladder cancer. The phase 3 EV-302 trial, also ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Bottom Line: Patients with localized muscle-invasive bladder cancer (MIBC ... Garcia-del-Muro has served as an advisor for Pfizer, Bristol Myers Squibb, Ipsen, Roche, PharmaMar, The GES Group ...

A phase 3 trial found that a combination of a Pfizer and Astellas drug ... improved survival rates for patients with advanced bladder cancer. The latest results from the trial, which focused ...